Trial Profile
Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy (Maintenance of Remission) and Safety of Etrolizumab Compared With Placebo in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Naive to TNF Inhibitors
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Etrolizumab (Primary)
- Indications Ulcerative colitis
- Focus Registrational; Therapeutic Use
- Acronyms LAUREL
- Sponsors Roche
- 23 May 2021 Results assessing post-etrolizumab treatment changes in inflammatory cells, activated fibroblasts and epithelial cell subsets in intestinal biopsies from patients enrolled in two clinical studies: LAUREL and HICKORY presented at the Digestive Disease Week 2021
- 13 Oct 2020 Results presented at the 28th United European Gastroenterology Week.
- 10 Aug 2020 According to a Roche media release, further analyses of the data, including secondary endpoints, are ongoing and will be submitted for presentation at upcoming medical meetings.